107 related articles for article (PubMed ID: 17651538)
61. A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patients.
Yau T; Cheng PNM; Chiu J; Kwok GGW; Leung R; Liu AM; Cheung TT; Ng CT
Invest New Drugs; 2022 Apr; 40(2):314-321. PubMed ID: 34735674
[TBL] [Abstract][Full Text] [Related]
62. A Study on the Tolerability of Capecitabine plus Oxaliplatin as Adjuvant Chemotherapy.
Nakanishi M; Kuriu Y; Murayama Y; Arita T; Kosuga T; Morimura R; Konishi H; Komatsu S; Shiozaki A; Ikoma H; Ichikawa D; Fujiwara H; Okamoto K; Otsuji E
Anticancer Res; 2016 Apr; 36(4):1851-4. PubMed ID: 27069169
[TBL] [Abstract][Full Text] [Related]
63. Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.
Hill A; Bergin P; Hanning F; Thompson P; Findlay M; Damianovich D; McKeage MJ
BMC Cancer; 2010 Aug; 10():451. PubMed ID: 20731872
[TBL] [Abstract][Full Text] [Related]
64. Severe disabling sensory-motor polyneuropathy during oxaliplatin-based chemotherapy.
Leonard GD; Wagner MR; Quinn MG; Grem JL
Anticancer Drugs; 2004 Aug; 15(7):733-5. PubMed ID: 15269607
[TBL] [Abstract][Full Text] [Related]
65. A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation.
Cascinu S; Berardi R; Salvagni S; Beretta GD; Catalano V; Pucci F; Sobrero A; Tagliaferri P; Labianca R; Scartozzi M; Crocicchio F; Mari E; Ardizzoni A
Br J Cancer; 2008 Jan; 98(1):71-6. PubMed ID: 18059397
[TBL] [Abstract][Full Text] [Related]
66. Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer.
Scartozzi M; Falcone A; Pucci F; Braconi C; Pierantoni C; Cavanna L; Franciosi V; Berardi R; Beretta G; Masi G; Allegrini G; Zaniboni A; Labianca R; Cascinu S
Tumori; 2006; 92(5):384-8. PubMed ID: 17168429
[TBL] [Abstract][Full Text] [Related]
67. Oxaliplatin-induced Lhermitte sign. A case report and review of literature.
Amaraneni A; Seth A; Itawi EA; Chandana SR
Clin Colorectal Cancer; 2014 Dec; 13(4):257-9. PubMed ID: 25442817
[No Abstract] [Full Text] [Related]
68. Combination Chemotherapy of Oxaliplatin and Capecitabine in Patients with Metastatic Colorectal Cancer: a Pilot Study.
Ahn MJ; Oh HS; Choi JH; Lee YY; Kim IS; Choi IY; Lee OY; Lee HW
Cancer Res Treat; 2003 Oct; 35(5):407-10. PubMed ID: 26680966
[TBL] [Abstract][Full Text] [Related]
69. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin.
Overman MJ; Morris V; Moinova H; Manyam G; Ensor J; Lee MS; Eng C; Kee B; Fogelman D; Shroff RT; LaFramboise T; Mazard T; Feng T; Hamilton S; Broom B; Lutterbaugh J; Issa JP; Markowitz SD; Kopetz S
Oncotarget; 2016 Oct; 7(41):67495-67506. PubMed ID: 27542211
[TBL] [Abstract][Full Text] [Related]
70. A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer.
Clamp AR; Schöffski P; Valle JW; Wilson RH; Marreaud S; Govaerts AS; Debois M; Lacombe D; Twelves C; Chick J; Jayson GC;
Cancer Chemother Pharmacol; 2008 Apr; 61(4):579-85. PubMed ID: 17520255
[TBL] [Abstract][Full Text] [Related]
71. [Interstitial lung disease induced by raltitrexed-oxaliplatin based chemotherapy for colorectal cancer: a case report].
Carreres-Prieto M; López-Sisamón D; Layos-Romero L
Farm Hosp; 2015 Mar; 39(2):118-9. PubMed ID: 25817092
[No Abstract] [Full Text] [Related]
72. Phenotyping breast cancer cell lines EM-G3, HCC1937, MCF7 and MDA-MB-231 using 2-D electrophoresis and affinity chromatography for glutathione-binding proteins.
Mladkova J; Sanda M; Matouskova E; Selicharova I
BMC Cancer; 2010 Aug; 10():449. PubMed ID: 20731849
[TBL] [Abstract][Full Text] [Related]
73. Development and Validation of HPLC and HPTLC Methods for Therapeutic Drug Monitoring of Capecitabine in Colorectal Cancer Patients.
Thorat SG; Chikhale RV; Tajne MR
J Chromatogr Sci; 2020 Jan; 57(10):892-900. PubMed ID: 31609432
[TBL] [Abstract][Full Text] [Related]
74. A rapid and simple HPTLC assay for therapeutic drug monitoring of capecitabine in colorectal cancer patients.
Thorat SG; Chikhale RV; Tajne MR
Biomed Chromatogr; 2018 Feb; 32(2):. PubMed ID: 28940404
[TBL] [Abstract][Full Text] [Related]
75. Complete response to capecitabine in a frail, elderly patient with metastatic colorectal cancer: A case report.
Fasano M; Fabozzi A; Giordano G; Venturini F; Aurilio G; Cantile F; Fabozzi T; Ricci V; Santabarbara G; Morgillo F; Ciardiello F; De Vita F
Oncol Lett; 2017 Feb; 13(2):979-983. PubMed ID: 28356988
[TBL] [Abstract][Full Text] [Related]
76. How best to treat older patients with metastatic colorectal cancer?
Taieb J
Lancet Gastroenterol Hepatol; 2019 May; 4(5):331-333. PubMed ID: 30852135
[No Abstract] [Full Text] [Related]
77. Treatment effects of oxaliplatin combined with gemcitabine on colorectal cancer and its influence on HMGB1 expression.
Wen S; Du X; Gou Y; Jiang L
Oncol Lett; 2016 Nov; 12(5):3187-3190. PubMed ID: 27899980
[TBL] [Abstract][Full Text] [Related]
78. [Chemotherapy in elderly frail patients with advanced colorectal cancer. MRC FOCUS 2 (UK Medical Research Council Fluorouracil, Oxaliplatin, and Capecitabine: Use and Sequencing)].
Wedding U; Nitschmann S
Internist (Berl); 2012 May; 53(5):635-9. PubMed ID: 22527668
[No Abstract] [Full Text] [Related]
79. Reply to Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study.
Rosati G
Ann Oncol; 2010 Oct; 21(10):2121-2122. PubMed ID: 32806470
[No Abstract] [Full Text] [Related]
80. Corrigendum to 'Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer', [Eur J Canc 51 (2015) 482-488].
Ryu MH; Yoo C; Kim JG; Ryoo BY; Park YS; Park SR; Han HS; Chung IJ; Song EK; Lee KH; Kang SY; Kang YK
Eur J Cancer; 2021 Apr; 147():187. PubMed ID: 33612368
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
